Clinical Edge Journal Scan

Key clinical point: Everolimus + exemestane demonstrated good efficacy and had a manageable safety profile in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC).

Major finding: Everolimus + exemestane led to a median progression-free survival (PFS) of 6.6 months (95% CI 6.3-7.0 months). PFS was more favorable among patients with a greater vs lower body mass index (≥25 vs 20 to <25 kg/m²; P < .0001); however, the survival outcomes were worse among patients with vs without visceral metastases (hazard ratio 1.417; P < .0001). Stomatitis (42.6%) and fatigue (19.8%) were the most frequent adverse events.

Study details: Findings are from a prospective, non-interventional study including 2074 postmenopausal women with HR+/HER2− advanced BC who received everolimus + exemestane.

Disclosures: This study was funded by Novartis Deutschland GmbH, Germany. Two authors declared being employees of or holding stocks in Novartis. Some authors declared receiving honoraria or personal fees or having other ties with Novartis and various other sources. Eight authors declared no conflicts of interest.

Source: Lüftner D, Schuetz F, Schneeweiss A, et al. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study. Int J Cancer. 2024 (Mar 6). doi: 10.1002/ijc.34912 Source

Key clinical point: Everolimus + exemestane demonstrated good efficacy and had a manageable safety profile in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC).

Major finding: Everolimus + exemestane led to a median progression-free survival (PFS) of 6.6 months (95% CI 6.3-7.0 months). PFS was more favorable among patients with a greater vs lower body mass index (≥25 vs 20 to <25 kg/m²; P < .0001); however, the survival outcomes were worse among patients with vs without visceral metastases (hazard ratio 1.417; P < .0001). Stomatitis (42.6%) and fatigue (19.8%) were the most frequent adverse events.

Study details: Findings are from a prospective, non-interventional study including 2074 postmenopausal women with HR+/HER2− advanced BC who received everolimus + exemestane.

Disclosures: This study was funded by Novartis Deutschland GmbH, Germany. Two authors declared being employees of or holding stocks in Novartis. Some authors declared receiving honoraria or personal fees or having other ties with Novartis and various other sources. Eight authors declared no conflicts of interest.

Source: Lüftner D, Schuetz F, Schneeweiss A, et al. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study. Int J Cancer. 2024 (Mar 6). doi: 10.1002/ijc.34912 Source

Key clinical point: Everolimus + exemestane demonstrated good efficacy and had a manageable safety profile in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC).

Major finding: Everolimus + exemestane led to a median progression-free survival (PFS) of 6.6 months (95% CI 6.3-7.0 months). PFS was more favorable among patients with a greater vs lower body mass index (≥25 vs 20 to <25 kg/m²; P < .0001); however, the survival outcomes were worse among patients with vs without visceral metastases (hazard ratio 1.417; P < .0001). Stomatitis (42.6%) and fatigue (19.8%) were the most frequent adverse events.

Study details: Findings are from a prospective, non-interventional study including 2074 postmenopausal women with HR+/HER2− advanced BC who received everolimus + exemestane.

Disclosures: This study was funded by Novartis Deutschland GmbH, Germany. Two authors declared being employees of or holding stocks in Novartis. Some authors declared receiving honoraria or personal fees or having other ties with Novartis and various other sources. Eight authors declared no conflicts of interest.

Source: Lüftner D, Schuetz F, Schneeweiss A, et al. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study. Int J Cancer. 2024 (Mar 6). doi: 10.1002/ijc.34912 Source

Key clinical point: Sentinel lymph node biopsy (SLNB), a less invasive strategy, resulted in comparable survival and regional disease control as axillary lymph node dissection (ALND) in patients with sentinel node-positive early breast cancer (BC) who underwent total mastectomy (TM).

Major finding: There were no significant differences in 5-year ipsilateral locoregional recurrence-free survival (LRRFS; P = .21), 5-year distant metastasis-free survival (P = .96), and disease-free survival (P > .05) between the SLNB-alone and ALND groups. However, receipt vs no receipt of radiation therapy improved local disease control in the SLNB group (5-year LRRFS; 100.0% vs 92.9%; P = .02).

Study details: Findings are from a retrospective study including 643 patients with early BC with 1-3 metastatic sentinel lymph nodes who underwent total mastectomy, of which 237 and 406 patients underwent SLNB alone and completion ALND, respectively.

Disclosures: The open access funding for this study was enabled and organized by Seoul National University. The authors declared no conflicts of interest.

Source: Chun JW, Kang E, Kim H-K, et al. Oncological safety of skipping axillary lymph node dissection in patients with clinical N0, sentinel node-positive breast cancer undergoing total mastectomy. Ann Surg Oncol. 2024 (Feb 17). doi: 10.1245/s10434-024-15049-7 Source

Key clinical point: Sentinel lymph node biopsy (SLNB), a less invasive strategy, resulted in comparable survival and regional disease control as axillary lymph node dissection (ALND) in patients with sentinel node-positive early breast cancer (BC) who underwent total mastectomy (TM).

Major finding: There were no significant differences in 5-year ipsilateral locoregional recurrence-free survival (LRRFS; P = .21), 5-year distant metastasis-free survival (P = .96), and disease-free survival (P > .05) between the SLNB-alone and ALND groups. However, receipt vs no receipt of radiation therapy improved local disease control in the SLNB group (5-year LRRFS; 100.0% vs 92.9%; P = .02).

Study details: Findings are from a retrospective study including 643 patients with early BC with 1-3 metastatic sentinel lymph nodes who underwent total mastectomy, of which 237 and 406 patients underwent SLNB alone and completion ALND, respectively.

Disclosures: The open access funding for this study was enabled and organized by Seoul National University. The authors declared no conflicts of interest.

Source: Chun JW, Kang E, Kim H-K, et al. Oncological safety of skipping axillary lymph node dissection in patients with clinical N0, sentinel node-positive breast cancer undergoing total mastectomy. Ann Surg Oncol. 2024 (Feb 17). doi: 10.1245/s10434-024-15049-7 Source

Key clinical point: Sentinel lymph node biopsy (SLNB), a less invasive strategy, resulted in comparable survival and regional disease control as axillary lymph node dissection (ALND) in patients with sentinel node-positive early breast cancer (BC) who underwent total mastectomy (TM).

Major finding: There were no significant differences in 5-year ipsilateral locoregional recurrence-free survival (LRRFS; P = .21), 5-year distant metastasis-free survival (P = .96), and disease-free survival (P > .05) between the SLNB-alone and ALND groups. However, receipt vs no receipt of radiation therapy improved local disease control in the SLNB group (5-year LRRFS; 100.0% vs 92.9%; P = .02).

Study details: Findings are from a retrospective study including 643 patients with early BC with 1-3 metastatic sentinel lymph nodes who underwent total mastectomy, of which 237 and 406 patients underwent SLNB alone and completion ALND, respectively.

Disclosures: The open access funding for this study was enabled and organized by Seoul National University. The authors declared no conflicts of interest.

Source: Chun JW, Kang E, Kim H-K, et al. Oncological safety of skipping axillary lymph node dissection in patients with clinical N0, sentinel node-positive breast cancer undergoing total mastectomy. Ann Surg Oncol. 2024 (Feb 17). doi: 10.1245/s10434-024-15049-7 Source

Key clinical point: The coexistence of obesity and family history of cancer significantly increased the risk for breast cancer (BC) in women, suggesting that weight management is important in women with a family history of cancer.

Major finding: The risk for BC was significantly higher in women with vs without a family history of BC (adjusted hazard ratio [aHR] 1.63; 95% CI 1.22-2.49). The risk was further elevated in women with a body mass index (BMI) ≥ 24 kg/m² and a family history of cancer vs women with BMI < 24 kg/m² and no family history of cancer (adjusted hazard ratio 2.06; 95% CI 1.39-3.06).

Study details: Findings are from a population-based prospective cohort study that included 15,055 women, of which 4210 women had a family history of cancer.

Disclosures: This study was supported by the Nature Science Foundation of Minhang district, Shanghai, China. The authors declared no conflicts of interest.

Source: Cao J, Li J, Zhang Z, et al. Interaction between body mass index and family history of cancer on the risk of female breast cancer. Sci Rep. 2024;14:4927 (Feb 28). doi: 10.1038/s41598-024-54762-x Source

Key clinical point: The coexistence of obesity and family history of cancer significantly increased the risk for breast cancer (BC) in women, suggesting that weight management is important in women with a family history of cancer.

Major finding: The risk for BC was significantly higher in women with vs without a family history of BC (adjusted hazard ratio [aHR] 1.63; 95% CI 1.22-2.49). The risk was further elevated in women with a body mass index (BMI) ≥ 24 kg/m² and a family history of cancer vs women with BMI < 24 kg/m² and no family history of cancer (adjusted hazard ratio 2.06; 95% CI 1.39-3.06).

Study details: Findings are from a population-based prospective cohort study that included 15,055 women, of which 4210 women had a family history of cancer.

Disclosures: This study was supported by the Nature Science Foundation of Minhang district, Shanghai, China. The authors declared no conflicts of interest.

Source: Cao J, Li J, Zhang Z, et al. Interaction between body mass index and family history of cancer on the risk of female breast cancer. Sci Rep. 2024;14:4927 (Feb 28). doi: 10.1038/s41598-024-54762-x Source

Key clinical point: The coexistence of obesity and family history of cancer significantly increased the risk for breast cancer (BC) in women, suggesting that weight management is important in women with a family history of cancer.

Major finding: The risk for BC was significantly higher in women with vs without a family history of BC (adjusted hazard ratio [aHR] 1.63; 95% CI 1.22-2.49). The risk was further elevated in women with a body mass index (BMI) ≥ 24 kg/m² and a family history of cancer vs women with BMI < 24 kg/m² and no family history of cancer (adjusted hazard ratio 2.06; 95% CI 1.39-3.06).

Study details: Findings are from a population-based prospective cohort study that included 15,055 women, of which 4210 women had a family history of cancer.

Disclosures: This study was supported by the Nature Science Foundation of Minhang district, Shanghai, China. The authors declared no conflicts of interest.

Source: Cao J, Li J, Zhang Z, et al. Interaction between body mass index and family history of cancer on the risk of female breast cancer. Sci Rep. 2024;14:4927 (Feb 28). doi: 10.1038/s41598-024-54762-x Source

Key clinical point: Compared with mastectomy, breast-conserving surgery (BCS) led to comparable locoregional recurrence (LRR; the first relapse site) events along with improved survival outcomes in patients with early-stage node-negative triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.

Major finding: BCS vs mastectomy following neoadjuvant chemotherapy did not increase LRR (P = .5209) and was significantly associated with improved disease-free survival (adjusted hazard ratio [aHR] 0.51; P < .001) and overall survival (aHR 0.43; P < .001). Absence of pathologic complete response was the only determinant for worsened LRR risk (HR 2.22; P = .001).

Study details: This retrospective analysis of eight prospective trials included 1074 neoadjuvant chemotherapy-treated patients with early-stage node-negative TNBC and available surgery data.

Disclosures: This study received financial support from Deutschen Forschungsgemeinschaft (DFG) within the funding program Open Access Publikationskosten. Three authors declared being employees of GBG Forschungs GmbH. Ninel authors declared receiving honoraria, grants, consulting fees, or personal fees or having other ties with various sources. The other authors had no conflicts to declare.

Source: Krug D, Vladimirova V, Untch M, et al. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast. 2024;74:103701 (Feb 24). doi: 10.1016/j.breast.2024.103701 Source

Key clinical point: Compared with mastectomy, breast-conserving surgery (BCS) led to comparable locoregional recurrence (LRR; the first relapse site) events along with improved survival outcomes in patients with early-stage node-negative triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.

Major finding: BCS vs mastectomy following neoadjuvant chemotherapy did not increase LRR (P = .5209) and was significantly associated with improved disease-free survival (adjusted hazard ratio [aHR] 0.51; P < .001) and overall survival (aHR 0.43; P < .001). Absence of pathologic complete response was the only determinant for worsened LRR risk (HR 2.22; P = .001).

Study details: This retrospective analysis of eight prospective trials included 1074 neoadjuvant chemotherapy-treated patients with early-stage node-negative TNBC and available surgery data.

Disclosures: This study received financial support from Deutschen Forschungsgemeinschaft (DFG) within the funding program Open Access Publikationskosten. Three authors declared being employees of GBG Forschungs GmbH. Ninel authors declared receiving honoraria, grants, consulting fees, or personal fees or having other ties with various sources. The other authors had no conflicts to declare.

Source: Krug D, Vladimirova V, Untch M, et al. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast. 2024;74:103701 (Feb 24). doi: 10.1016/j.breast.2024.103701 Source

Key clinical point: Compared with mastectomy, breast-conserving surgery (BCS) led to comparable locoregional recurrence (LRR; the first relapse site) events along with improved survival outcomes in patients with early-stage node-negative triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.

Major finding: BCS vs mastectomy following neoadjuvant chemotherapy did not increase LRR (P = .5209) and was significantly associated with improved disease-free survival (adjusted hazard ratio [aHR] 0.51; P < .001) and overall survival (aHR 0.43; P < .001). Absence of pathologic complete response was the only determinant for worsened LRR risk (HR 2.22; P = .001).

Study details: This retrospective analysis of eight prospective trials included 1074 neoadjuvant chemotherapy-treated patients with early-stage node-negative TNBC and available surgery data.

Disclosures: This study received financial support from Deutschen Forschungsgemeinschaft (DFG) within the funding program Open Access Publikationskosten. Three authors declared being employees of GBG Forschungs GmbH. Ninel authors declared receiving honoraria, grants, consulting fees, or personal fees or having other ties with various sources. The other authors had no conflicts to declare.

Source: Krug D, Vladimirova V, Untch M, et al. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast. 2024;74:103701 (Feb 24). doi: 10.1016/j.breast.2024.103701 Source

Key clinical point: The risk for breast cancer (BC) was significantly elevated in female 5-year survivors of Hodgkin lymphoma (HL) who were treated with doxorubicin between the ages of 15 and 50 years.

Major finding: The risk for BC was 1.4 times higher (95% CI 1.04-1.9) in survivors of HL who did vs did not receive doxorubicin, with the risk increasing further in survivors who received a cumulative doxorubicin dose > 200 mg/m² (adjusted hazard ratio 1.5; 95% CI 1.08-2.1). In fact, every 100 mg/m² increase in doxorubicin dose increased the risk for BC by 1.18 times (95% CI 1.05-1.32).

Study details: Findings are from a cohort study including 5-year survivors of HL (n = 1964) who received treatment between the ages of 15 and 50 years, of whom 1113 patients received doxorubicin.

Disclosures: This study was supported by grants from the Dutch Cancer Society, Netherlands. Five authors declared receiving honoraria, research funding, travel, accommodations, or other expenses from or serving in consulting or advisory roles or as speakers' bureau members for various sources.

Source: Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol. 2024 (Feb 15). doi: 10.1200/JCO.23.01386 Source

Key clinical point: The risk for breast cancer (BC) was significantly elevated in female 5-year survivors of Hodgkin lymphoma (HL) who were treated with doxorubicin between the ages of 15 and 50 years.

Major finding: The risk for BC was 1.4 times higher (95% CI 1.04-1.9) in survivors of HL who did vs did not receive doxorubicin, with the risk increasing further in survivors who received a cumulative doxorubicin dose > 200 mg/m² (adjusted hazard ratio 1.5; 95% CI 1.08-2.1). In fact, every 100 mg/m² increase in doxorubicin dose increased the risk for BC by 1.18 times (95% CI 1.05-1.32).

Study details: Findings are from a cohort study including 5-year survivors of HL (n = 1964) who received treatment between the ages of 15 and 50 years, of whom 1113 patients received doxorubicin.

Disclosures: This study was supported by grants from the Dutch Cancer Society, Netherlands. Five authors declared receiving honoraria, research funding, travel, accommodations, or other expenses from or serving in consulting or advisory roles or as speakers' bureau members for various sources.

Source: Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol. 2024 (Feb 15). doi: 10.1200/JCO.23.01386 Source

Key clinical point: The risk for breast cancer (BC) was significantly elevated in female 5-year survivors of Hodgkin lymphoma (HL) who were treated with doxorubicin between the ages of 15 and 50 years.

Major finding: The risk for BC was 1.4 times higher (95% CI 1.04-1.9) in survivors of HL who did vs did not receive doxorubicin, with the risk increasing further in survivors who received a cumulative doxorubicin dose > 200 mg/m² (adjusted hazard ratio 1.5; 95% CI 1.08-2.1). In fact, every 100 mg/m² increase in doxorubicin dose increased the risk for BC by 1.18 times (95% CI 1.05-1.32).

Study details: Findings are from a cohort study including 5-year survivors of HL (n = 1964) who received treatment between the ages of 15 and 50 years, of whom 1113 patients received doxorubicin.

Disclosures: This study was supported by grants from the Dutch Cancer Society, Netherlands. Five authors declared receiving honoraria, research funding, travel, accommodations, or other expenses from or serving in consulting or advisory roles or as speakers' bureau members for various sources.

Source: Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol. 2024 (Feb 15). doi: 10.1200/JCO.23.01386 Source

Key clinical point: Enobosarm, a selective androgen receptor modulator, showed antitumor activity and an acceptable safety profile in pretreated women with estrogen receptor-positive (ER+), androgen receptor-positive (AR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC).

Major finding: The clinical benefit rate was ~30% at 24 weeks, with 32% and 29% of patients showing clinical benefits with 9 mg and 18 mg enobosarm, respectively. Grades 3-4 treatment-related adverse events were reported by 8% and 16% of patients in the 9 mg and 18 mg enobosarm groups, respectively.

Study details: Findings are from a phase 2 study that included 136 pretreated postmenopausal women with ER+/HER2− locally advanced or metastatic BC who were randomly assigned to receive 9 mg or 18 mg enobosarm daily, of whom 102 women had AR+ BC.

Disclosures: This study was funded by GTx. Several authors declared receiving grants or honoraria from; serving in consulting, leadership, or advisory roles for; owning patents with or stocks of; or having other ties with various sources, including GTx.

Source: Palmieri C, Linden H, Birrell SN, et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): A randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 2024;25(3):317-325 (Feb 8). doi: 10.1016/S1470-2045(24)00004-4 Source

Key clinical point: Enobosarm, a selective androgen receptor modulator, showed antitumor activity and an acceptable safety profile in pretreated women with estrogen receptor-positive (ER+), androgen receptor-positive (AR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC).

Major finding: The clinical benefit rate was ~30% at 24 weeks, with 32% and 29% of patients showing clinical benefits with 9 mg and 18 mg enobosarm, respectively. Grades 3-4 treatment-related adverse events were reported by 8% and 16% of patients in the 9 mg and 18 mg enobosarm groups, respectively.

Study details: Findings are from a phase 2 study that included 136 pretreated postmenopausal women with ER+/HER2− locally advanced or metastatic BC who were randomly assigned to receive 9 mg or 18 mg enobosarm daily, of whom 102 women had AR+ BC.

Disclosures: This study was funded by GTx. Several authors declared receiving grants or honoraria from; serving in consulting, leadership, or advisory roles for; owning patents with or stocks of; or having other ties with various sources, including GTx.

Source: Palmieri C, Linden H, Birrell SN, et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): A randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 2024;25(3):317-325 (Feb 8). doi: 10.1016/S1470-2045(24)00004-4 Source

Key clinical point: Enobosarm, a selective androgen receptor modulator, showed antitumor activity and an acceptable safety profile in pretreated women with estrogen receptor-positive (ER+), androgen receptor-positive (AR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC).

Major finding: The clinical benefit rate was ~30% at 24 weeks, with 32% and 29% of patients showing clinical benefits with 9 mg and 18 mg enobosarm, respectively. Grades 3-4 treatment-related adverse events were reported by 8% and 16% of patients in the 9 mg and 18 mg enobosarm groups, respectively.

Study details: Findings are from a phase 2 study that included 136 pretreated postmenopausal women with ER+/HER2− locally advanced or metastatic BC who were randomly assigned to receive 9 mg or 18 mg enobosarm daily, of whom 102 women had AR+ BC.

Disclosures: This study was funded by GTx. Several authors declared receiving grants or honoraria from; serving in consulting, leadership, or advisory roles for; owning patents with or stocks of; or having other ties with various sources, including GTx.

Source: Palmieri C, Linden H, Birrell SN, et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): A randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 2024;25(3):317-325 (Feb 8). doi: 10.1016/S1470-2045(24)00004-4 Source

Key clinical point: Women who received adjuvant radiotherapy for breast cancer (BC) reported a significant reduction in pain and fibrosis upon completing hyperbaric oxygen therapy (HBOT).

Major finding: Only 25% of women accepted and completed HBOT treatment. A smaller proportion of women who completed HBOT vs those who would have completed HBOT if offered reported moderate or severe pain in breast, chest wall, or shoulder (32% vs 75%; adjusted odds ratio [aOR] 0.34; P = .01) and moderate or severe fibrosis (17% vs 86%; aOR 0.14; P = .001).

Study details: Findings are from the phase 3 HONEY trial which included 189 women with invasive BC or ductal carcinoma in situ who reported late local toxic effects after adjuvant radiotherapy and were randomly assigned to receive HBOT (n = 125) or usual follow-up care (n = 61).

Disclosures: This study was partially funded by The Da Vinci Clinic, the Netherlands. The authors declared no conflicts of interest.

Source: Mink van der Molen DR, Batenburg MCT, Maarse W, et al. Hyperbaric oxygen therapy and late local toxic effects in patients with irradiated breast cancer: A randomized clinical trial. JAMA Oncol. 2024 (Feb 8). doi: 10.1001/jamaoncol.2023.6776 Source

Key clinical point: Women who received adjuvant radiotherapy for breast cancer (BC) reported a significant reduction in pain and fibrosis upon completing hyperbaric oxygen therapy (HBOT).

Major finding: Only 25% of women accepted and completed HBOT treatment. A smaller proportion of women who completed HBOT vs those who would have completed HBOT if offered reported moderate or severe pain in breast, chest wall, or shoulder (32% vs 75%; adjusted odds ratio [aOR] 0.34; P = .01) and moderate or severe fibrosis (17% vs 86%; aOR 0.14; P = .001).

Study details: Findings are from the phase 3 HONEY trial which included 189 women with invasive BC or ductal carcinoma in situ who reported late local toxic effects after adjuvant radiotherapy and were randomly assigned to receive HBOT (n = 125) or usual follow-up care (n = 61).

Disclosures: This study was partially funded by The Da Vinci Clinic, the Netherlands. The authors declared no conflicts of interest.

Source: Mink van der Molen DR, Batenburg MCT, Maarse W, et al. Hyperbaric oxygen therapy and late local toxic effects in patients with irradiated breast cancer: A randomized clinical trial. JAMA Oncol. 2024 (Feb 8). doi: 10.1001/jamaoncol.2023.6776 Source

Key clinical point: Women who received adjuvant radiotherapy for breast cancer (BC) reported a significant reduction in pain and fibrosis upon completing hyperbaric oxygen therapy (HBOT).

Major finding: Only 25% of women accepted and completed HBOT treatment. A smaller proportion of women who completed HBOT vs those who would have completed HBOT if offered reported moderate or severe pain in breast, chest wall, or shoulder (32% vs 75%; adjusted odds ratio [aOR] 0.34; P = .01) and moderate or severe fibrosis (17% vs 86%; aOR 0.14; P = .001).

Study details: Findings are from the phase 3 HONEY trial which included 189 women with invasive BC or ductal carcinoma in situ who reported late local toxic effects after adjuvant radiotherapy and were randomly assigned to receive HBOT (n = 125) or usual follow-up care (n = 61).

Disclosures: This study was partially funded by The Da Vinci Clinic, the Netherlands. The authors declared no conflicts of interest.

Source: Mink van der Molen DR, Batenburg MCT, Maarse W, et al. Hyperbaric oxygen therapy and late local toxic effects in patients with irradiated breast cancer: A randomized clinical trial. JAMA Oncol. 2024 (Feb 8). doi: 10.1001/jamaoncol.2023.6776 Source

Key clinical point: Among women with BRCA1 sequence variation, magnetic resonance imaging (MRI) surveillance reduces the risk for breast cancer (BC) mortality by 80% and can be offered to those aged 30 years or older.

Major finding: After a mean follow-up of 9.2 years, 344 women developed BC and 35 died due to BC. Among women who did vs did not undergo MRI surveillance, the reduction in BC mortality risk was 80% among those with BRCA1 sequence variation (hazard ratio [HR] 0.20; P < .001) but was not significant among those with BRCA2 sequence variation.

Study details: This cohort study included 2488 women (age ≥ 30 years) with BRCA1 or BRCA2 sequence variation, of which 1756 women underwent at least one MRI screening.

Disclosures: This study was supported by the Canadian Institutes of Health Research and others. Several authors declared receiving grants or personal fees or having other ties with various sources.

Source: Lubinski J, Kotsopoulos J, Moller P, et al, for the Hereditary Breast Cancer Clinical Study Group. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 2024 (Feb 29). doi: 10.1001/jamaoncol.2023.6944 Source

Key clinical point: Among women with BRCA1 sequence variation, magnetic resonance imaging (MRI) surveillance reduces the risk for breast cancer (BC) mortality by 80% and can be offered to those aged 30 years or older.

Major finding: After a mean follow-up of 9.2 years, 344 women developed BC and 35 died due to BC. Among women who did vs did not undergo MRI surveillance, the reduction in BC mortality risk was 80% among those with BRCA1 sequence variation (hazard ratio [HR] 0.20; P < .001) but was not significant among those with BRCA2 sequence variation.

Study details: This cohort study included 2488 women (age ≥ 30 years) with BRCA1 or BRCA2 sequence variation, of which 1756 women underwent at least one MRI screening.

Disclosures: This study was supported by the Canadian Institutes of Health Research and others. Several authors declared receiving grants or personal fees or having other ties with various sources.

Source: Lubinski J, Kotsopoulos J, Moller P, et al, for the Hereditary Breast Cancer Clinical Study Group. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 2024 (Feb 29). doi: 10.1001/jamaoncol.2023.6944 Source

Key clinical point: Among women with BRCA1 sequence variation, magnetic resonance imaging (MRI) surveillance reduces the risk for breast cancer (BC) mortality by 80% and can be offered to those aged 30 years or older.

Major finding: After a mean follow-up of 9.2 years, 344 women developed BC and 35 died due to BC. Among women who did vs did not undergo MRI surveillance, the reduction in BC mortality risk was 80% among those with BRCA1 sequence variation (hazard ratio [HR] 0.20; P < .001) but was not significant among those with BRCA2 sequence variation.

Study details: This cohort study included 2488 women (age ≥ 30 years) with BRCA1 or BRCA2 sequence variation, of which 1756 women underwent at least one MRI screening.

Disclosures: This study was supported by the Canadian Institutes of Health Research and others. Several authors declared receiving grants or personal fees or having other ties with various sources.

Source: Lubinski J, Kotsopoulos J, Moller P, et al, for the Hereditary Breast Cancer Clinical Study Group. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 2024 (Feb 29). doi: 10.1001/jamaoncol.2023.6944 Source

Key clinical point: Increased cytokine S100A8/9 expression on the skin surface in infants with a high risk for atopic dermatitis (AD) at 2 months with filaggrin wild genotype (FLGwt), but not filaggrin loss-of-function mutations (FLGmut), is predictive of AD development and persistence in the first year of life.

Major finding: Increased S100A8/9 titers detected in skin swabs of the antecubital fossa at 8 weeks in infants with FLGwt, but not in those with FLGmut, were associated with AD development in the first year of life (P = .033) and AD persistence of between 6 and 12 months of age (P < .001).

Study details: This single-center study included 86 infants from the STOP AD trial who had at least one parent with a history of AD, asthma, or allergic rhinitis and had either FLGwt or FLGmut.

Disclosures: The cost of the sample analysis was funded by Janssen R&D and Johnson & Johnson Santé Beauté France and the product used in the study was provided by Johnson & Johnson Santé Beauté France. Six authors declared being employees of or having other ties with the Johnson & Johnson family of companies and others. Two authors are coauthors on a patent application in relation to the STOP-AD study. No declaration of conflicting interests was made by CNC.

Source: Stamatas GN, Sato T, Ni Chaoimh C, et al. Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants. J Allergy Clin Immunol. 2024 (Mar 7). doi: 10.1016/j.jaci.2024.02.018 Source

Key clinical point: Increased cytokine S100A8/9 expression on the skin surface in infants with a high risk for atopic dermatitis (AD) at 2 months with filaggrin wild genotype (FLGwt), but not filaggrin loss-of-function mutations (FLGmut), is predictive of AD development and persistence in the first year of life.

Major finding: Increased S100A8/9 titers detected in skin swabs of the antecubital fossa at 8 weeks in infants with FLGwt, but not in those with FLGmut, were associated with AD development in the first year of life (P = .033) and AD persistence of between 6 and 12 months of age (P < .001).

Study details: This single-center study included 86 infants from the STOP AD trial who had at least one parent with a history of AD, asthma, or allergic rhinitis and had either FLGwt or FLGmut.

Disclosures: The cost of the sample analysis was funded by Janssen R&D and Johnson & Johnson Santé Beauté France and the product used in the study was provided by Johnson & Johnson Santé Beauté France. Six authors declared being employees of or having other ties with the Johnson & Johnson family of companies and others. Two authors are coauthors on a patent application in relation to the STOP-AD study. No declaration of conflicting interests was made by CNC.

Source: Stamatas GN, Sato T, Ni Chaoimh C, et al. Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants. J Allergy Clin Immunol. 2024 (Mar 7). doi: 10.1016/j.jaci.2024.02.018 Source

Key clinical point: Increased cytokine S100A8/9 expression on the skin surface in infants with a high risk for atopic dermatitis (AD) at 2 months with filaggrin wild genotype (FLGwt), but not filaggrin loss-of-function mutations (FLGmut), is predictive of AD development and persistence in the first year of life.

Major finding: Increased S100A8/9 titers detected in skin swabs of the antecubital fossa at 8 weeks in infants with FLGwt, but not in those with FLGmut, were associated with AD development in the first year of life (P = .033) and AD persistence of between 6 and 12 months of age (P < .001).

Study details: This single-center study included 86 infants from the STOP AD trial who had at least one parent with a history of AD, asthma, or allergic rhinitis and had either FLGwt or FLGmut.

Disclosures: The cost of the sample analysis was funded by Janssen R&D and Johnson & Johnson Santé Beauté France and the product used in the study was provided by Johnson & Johnson Santé Beauté France. Six authors declared being employees of or having other ties with the Johnson & Johnson family of companies and others. Two authors are coauthors on a patent application in relation to the STOP-AD study. No declaration of conflicting interests was made by CNC.

Source: Stamatas GN, Sato T, Ni Chaoimh C, et al. Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants. J Allergy Clin Immunol. 2024 (Mar 7). doi: 10.1016/j.jaci.2024.02.018 Source

Key clinical point: Safety is the most valued treatment attribute for adults with moderate-to-severe atopic dermatitis (AD), followed by the mode of administration, whereas monitoring requirements is the least critical attribute.

Major finding: The risk for severe adverse events emerged as the most important attribute (coefficient 0.42; 95% CI 0.36-0.49), followed by the ease of treatment administration with daily oral pills vs biweekly injections (coefficient 0.41, 95% CI 0.35-0.48). Avoiding monitoring for severe adverse events was the least critical attribute (coefficient 0.02; 95% CI −0.03 to 0.07).

Study details: This study included 713 adults with moderate-to-severe AD having Patient-Oriented Eczema Measure scores > 7 or current or prior exposure to systemic treatment who completed the online discrete choice experiment survey for treatment preferences in AD.

Disclosures: This study was sponsored by LEO Pharma. Five authors declared being employees of LEO Pharma or EY Economics Denmark, a paid vendor of LEO Pharma. Some authors declared serving as advisors, consultants, etc., for or receiving research grants, etc., from LEO Pharma and others.

Source: Ameen M, Alhusayen R, Brandi H, et al. Patient preferences in the treatment of moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2024 (Feb 21). doi: 10.2340/actadv.v104.19454 Source

Key clinical point: Safety is the most valued treatment attribute for adults with moderate-to-severe atopic dermatitis (AD), followed by the mode of administration, whereas monitoring requirements is the least critical attribute.

Major finding: The risk for severe adverse events emerged as the most important attribute (coefficient 0.42; 95% CI 0.36-0.49), followed by the ease of treatment administration with daily oral pills vs biweekly injections (coefficient 0.41, 95% CI 0.35-0.48). Avoiding monitoring for severe adverse events was the least critical attribute (coefficient 0.02; 95% CI −0.03 to 0.07).

Study details: This study included 713 adults with moderate-to-severe AD having Patient-Oriented Eczema Measure scores > 7 or current or prior exposure to systemic treatment who completed the online discrete choice experiment survey for treatment preferences in AD.

Disclosures: This study was sponsored by LEO Pharma. Five authors declared being employees of LEO Pharma or EY Economics Denmark, a paid vendor of LEO Pharma. Some authors declared serving as advisors, consultants, etc., for or receiving research grants, etc., from LEO Pharma and others.

Source: Ameen M, Alhusayen R, Brandi H, et al. Patient preferences in the treatment of moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2024 (Feb 21). doi: 10.2340/actadv.v104.19454 Source

Key clinical point: Safety is the most valued treatment attribute for adults with moderate-to-severe atopic dermatitis (AD), followed by the mode of administration, whereas monitoring requirements is the least critical attribute.

Major finding: The risk for severe adverse events emerged as the most important attribute (coefficient 0.42; 95% CI 0.36-0.49), followed by the ease of treatment administration with daily oral pills vs biweekly injections (coefficient 0.41, 95% CI 0.35-0.48). Avoiding monitoring for severe adverse events was the least critical attribute (coefficient 0.02; 95% CI −0.03 to 0.07).

Study details: This study included 713 adults with moderate-to-severe AD having Patient-Oriented Eczema Measure scores > 7 or current or prior exposure to systemic treatment who completed the online discrete choice experiment survey for treatment preferences in AD.

Disclosures: This study was sponsored by LEO Pharma. Five authors declared being employees of LEO Pharma or EY Economics Denmark, a paid vendor of LEO Pharma. Some authors declared serving as advisors, consultants, etc., for or receiving research grants, etc., from LEO Pharma and others.

Source: Ameen M, Alhusayen R, Brandi H, et al. Patient preferences in the treatment of moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2024 (Feb 21). doi: 10.2340/actadv.v104.19454 Source